M. Ashraf
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
M. Ashraf has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
S Nayak
Department of Surgical Oncology, Chittaranjan National Cancer Institute (CNCI), 37, S P Mukherjee Road, Kolkata-26, India
2 shared publicationsA Bhowmick
Department of Head and Neck Surgery, Chittaranjan National Cancer Institute (CNCI), 37, S P Mukherjee Road, Kolkata-26, India
1 shared publicationA. Dam
Department of Head and Neck Surgery, Chittaranjan National Cancer Institute (CNCI), 37, S P Mukherjee Road, Kolkata-26, India
1 shared publicationJ Biswas
1 shared publicationJ. Biswas
Department of Surgical Oncology, Chittaranjan National Cancer Institute (CNCI), 37, S P Mukherjee Road, Kolkata-26, India
1 shared publicationJk. Jha
Department of Surgical Oncology, Chittaranjan National Cancer Institute (CNCI), 37, S P Mukherjee Road, Kolkata-26, India
1 shared publication
Latest Publications
- Open Access
- 1 January 2010
- Published by Elmer Press, Inc. in World Journal of Oncology
- Vol. 1 (1) , 28-34-34
Results of Treatment of Squamous Cell Carcinoma of Maxillary Sinus: A 26-Year Experience
Background: Five-year survival in squamous cell carcinoma of maxillary antrum is low. This article examines the results of various approaches to treatment as given in our hospital in past 26 years. Methods: From 1979 to 2005, 379 patients with squamous cell carcinoma of maxillary antrum managed with curative intent were studied. Twenty-eight patients had T2, 237 patients had T3, and 114 had T4 tumors. The N classification was N0 in 316 patients, N1 in 21 patients, N2a in 28 patients and N2b in 14 patients. Treatment to the primary site comprised of surgery (Sx) and radiation therapy (RT) in 284 patients, RT alone in 57 patients and chemotherapy (CTx) with radiotherapy in 38 patients. Results: There was a difference in survival between patients who underwent Sx with RT compared with patients who received RT alone or CTx with RT. The most common pattern of recurrence was in the primary site, 187 (49.3%) patients. Local control at 3 and 5 years was 71% and 63.8% respectively in Sx with RT, 31.6% and 28% respectively in RT, and 28.9% and 26% in CTx with RT group. Conclusions: The type of treatment to the primary site is an important determinant of survival and local control. Surgery with radiation is a better treatment option. doi:10.4021/wjon2010.02.191w
- 1 January 2010
- Published by Elmer Press, Inc. in World Journal of Oncology
- Vol. 1 (1) , 28-34-34
Open AccessResults of Treatment of Squamous Cell Carcinoma of Maxillary Sinus: A 26-Year Experience
Background: Five-year survival in squamous cell carcinoma of maxillary antrum is low. This article examines the results of various approaches to treatment as given in our hospital in past 26 years. Methods: From 1979 to 2005, 379 patients with squamous cell carcinoma of maxillary antrum managed with curative intent were studied. Twenty-eight patients had T2, 237 patients had T3, and 114 had T4 tumors. The N classification was N0 in 316 patients, N1 in 21 patients, N2a in 28 patients and N2b in 14 patients. Treatment to the primary site comprised of surgery (Sx) and radiation therapy (RT) in 284 patients, RT alone in 57 patients and chemotherapy (CTx) with radiotherapy in 38 patients. Results: There was a difference in survival between patients who underwent Sx with RT compared with patients who received RT alone or CTx with RT. The most common pattern of recurrence was in the primary site, 187 (49.3%) patients. Local control at 3 and 5 years was 71% and 63.8% respectively in Sx with RT, 31.6% and 28% respectively in RT, and 28.9% and 26% in CTx with RT group. Conclusions: The type of treatment to the primary site is an important determinant of survival and local control. Surgery with radiation is a better treatment option. doi:10.4021/wjon2010.02.191w
- 16 October 2009
- Vol. 10 (4) , 609-12
Tamoxifen use in Indian women--adverse effects revisited.
Tamoxifen is generally considered a safe drug for Indian women with breast cancer. Indian women seem to tolerate tamoxifen therapy better than western women, but there are no data regarding safety and local adverse effect profiles in typical Indian populations. A total of 3,000 case records of patients who had received tamoxifen daily for any period of time, between January 1988 and December 2007, were identified for study. Hot flashes were reported by 800 (26%), mild vaginal dryness by 450 (15%) and vaginal discharge by 300 (10%), with vaginal bleeding experienced by 40 (1.3%) patients. A total of 1,100 (36.6%) asymptomatic patients had a thickened endometrium(defined as >8mm in thickness) on ultrasonography. Endometrial curettage was performed in all of these. None of the patients developed endometrial carcinoma. Fatty infiltration of liver was found in 1,440 (48%) patients with a mean time interval for development of 7 months (range 6-30 months). Fatty infiltration of liver is found in almost half of the Eastern Indian women who receive tamoxifen. Increased endometrial thickness, which remains asymptomatic, was documented in more than one third of patients on ultrasound examination. Tamoxifen seems to have a negligible potential for causation of uterine malignancies in eastern Indian women. Rates of hysterectomies in Indian patients on tamoxifen are substantially lower than those of western patients on tamoxifen.
- 16 October 2009
- Vol. 10 (4) , 609-12
Tamoxifen use in Indian women--adverse effects revisited.
Tamoxifen is generally considered a safe drug for Indian women with breast cancer. Indian women seem to tolerate tamoxifen therapy better than western women, but there are no data regarding safety and local adverse effect profiles in typical Indian populations. A total of 3,000 case records of patients who had received tamoxifen daily for any period of time, between January 1988 and December 2007, were identified for study. Hot flashes were reported by 800 (26%), mild vaginal dryness by 450 (15%) and vaginal discharge by 300 (10%), with vaginal bleeding experienced by 40 (1.3%) patients. A total of 1,100 (36.6%) asymptomatic patients had a thickened endometrium(defined as >8mm in thickness) on ultrasonography. Endometrial curettage was performed in all of these. None of the patients developed endometrial carcinoma. Fatty infiltration of liver was found in 1,440 (48%) patients with a mean time interval for development of 7 months (range 6-30 months). Fatty infiltration of liver is found in almost half of the Eastern Indian women who receive tamoxifen. Increased endometrial thickness, which remains asymptomatic, was documented in more than one third of patients on ultrasound examination. Tamoxifen seems to have a negligible potential for causation of uterine malignancies in eastern Indian women. Rates of hysterectomies in Indian patients on tamoxifen are substantially lower than those of western patients on tamoxifen.